Zinc is an essential micronutrient crucial for the normal functioning of the human immune system. Zinc deficiency impairs immune function and increases infection risk, especially in vulnerable populations like people living with HIV. This project aims to study the role of zinc supplementation in improving immune response in HIV-infected individuals who are Immunological Non-Responders (INRs)-people who have not restored Cluster of differentiation 4 (CD4) T-cell counts despite receiving antiretroviral therapy (ART). INRs face a higher risk of opportunistic infections, non-HIV comorbidities due to high inflammation, and generally have a poorer prognosis. Zinc supports immune function by aiding in immune cell development, cytokine production, and maintaining mucosal barrier integrity.
Several studies have investigated zinc supplementation in HIV-infected individuals, showing significant increases in CD4 counts and a reduction in opportunistic infections. However, the doses used vary, and the results are sometimes contradictory. Our objective is to study whether zinc supplementation in INRs improves immune function, specifically by increasing CD4 counts, decreasing inflammation, and affecting other immune parameters.
This project involves a clinical trial where INRs will be randomly assigned to receive 75mg of elemental zinc daily (in the form of 3 zinc acetate tablets) along with their usual treatment or to continue their treatment without zinc supplements. We will assess whether zinc supplementation increases CD4 lymphocytes, reduces inflammation in INRs, and induces immune system changes. We will also investigate immune system functionality by measuring the presence of the Torque Teno Virus (TTV), a harmless virus, and see how zinc supplementation impacts its control by monitoring viral load changes.
Recent research by our group has demonstrated that zinc has both antiviral and anti-inflammatory effects. Zinc supplementation is generally safe and well-tolerated, with few adverse effects. Zinc is available in various forms, including gluconate, acetate, and sulfate. Although the recommended daily dose is 40mg, studies have shown that doses exceeding 80mg have been safely administered for over 10 years without side effects.
We have selected a 75mg daily dose of elemental zinc for several reasons. Studies that showed no effect used lower doses (15-20mg/day), and our research found that 75mg/day improved outcomes in acute viral infections like Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2). We believe previous failures to show zinc's efficacy were due to insufficient dosing. After extensive literature review, we concluded that 75mg daily is safe and likely to produce the desired effects.
Our goal is to demonstrate the efficacy of zinc as an immunomodulatory agent. If successful, this could be a simple and cost-effective way to improve the quality of life for many people. We would recommend its widespread use under medical supervision, particularly at the doses being studied.

Start Date02 Jan 2025

Sponsor / Collaborator

Consorci Mar Parc de Salut de Barcelona

[+1]

CTRI/2024/11/077282

/ Not yet recruitingPhase 4

A Clinical Study to Evaluate the Anti-sebum activity of Plum Green Tea and Zinc Sunscreen SPF 50 - NIL

Start Date03 Dec 2024

Sponsor / Collaborator-

TCTR20241027001

/ Not yet recruitingPhase 4IIT

Efficacy of zinc supplement on tinnitus: A double-blind randomized controlled trial

Start Date02 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with Zinc Acetate

100 Translational Medicine associated with Zinc Acetate

100 Patents (Medical) associated with Zinc Acetate

229,712

Literatures (Medical) associated with Zinc Acetate

31 Dec 2025·Energy Sources Part A-Recovery Utilization and Environmental Effects

Simultaneous improvement in qualities of bio-oil and syngas from catalytic pyrolysis of rice husk by demineralization

Author: Wang, Zhongwen ; Xiong, Yuanquan

This study aims to investigate the influences of different demineralization pretreatment processes on the properties of liquid and gas products from catalytic pyrolysis via activated carbon catalyst.To achieve this goal, deionized water, hydrochloric acid, and acetic acid were used to remove ash.The results indicated that leaching could remove a large amount of alkali and alk. earth metals (AAEMs).Besides, the experiments of different leaching solutions on catalytic fast pyrolysis of rice husks were conducted.It can be found that compared with direct pyrolysis, the catalytic pyrolysis produced more gas products, in which CO increased by 6.49%, while the bio-oil was concentrated in phenols (more than 90%).After demineralization, the content of CO in gas products further increased by 8.04%, while the relative content of phenol in bio-oil enhanced by 14.79% as well.Catalysis can enrich phenol in bio-oil, and leaching can enhance this enrichment.Meanwhile, demineralization can further improve the quality of syngas.The sample after demineralization by hydrochloric acid performed best on catalytic fast pyrolysis, where CO accounts for 57.68% volume of gaseous product and phenol accounted for 68.21% of bio-oil.

01 Jul 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Maximizing carbohydrate recovery and lignin fractionation from bamboo through in-situ synthesis of peracetic acid via mild ethyl acetate-hydrogen peroxide treatment

Author: Zhang, Junhua ; Wen, Peiyao ; He, Yucai ; Ying, Wenjun ; Yang, Dong

Peracetic acid is regarded as a green solvent for selective delignification in biomass biorefinery.However, its high cost and explosive nature in concentrated forms limit its practicality.In this study, a promising Et acetate-hydrogen peroxide (EA-HP) treatment was developed for the in-situ production of peracetic acid, aiming to efficiently fractionate lignin and carbohydrates from bamboo.Under the optimal conditions at 50°C for 20 h, a peak concentration of peracetic acid generated in-situ by the EA-HP treatment was recorded at 1.7%.This treatment demonstrated outstanding delignification capacity, achieving 95.3% delignification and maximum carbohydrate recoveries of 92.3% and 83.3% for cellulose and hemicellulose, resp.The treatment exhibited selective delignification of bamboo, and the removal of amorphous fraction enhanced the enzymic hydrolysis properties.Finally, lignin oxidation products, such as quinones and carboxylic acids, were identified, elucidating the mechanism of conversion of lignin from aromatic polymers to open-chain structures in the EA-HP system.The present paper proposed a treatment approach achieving efficient delignification and maximizing carbohydrate recovery, and provided a unique concept of biorefinery process.

01 Jul 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Does high hydrophilic complexing agent concentration enhance separation factors in “push-pull” extraction systems?

Author: Zhao, Qi ; Shih, Kaimin

General equations describing the separation factors applicable to "push-pull" extraction systems using neutral and acidic organophosphorus extractants were derived.Factors affecting the separation factors, such as complexation constants, extraction equilibrium constants, counter anion concentration, extractant content, and hydrophilic complexing agent concentration, were elucidated.Specifically, for the extraction systems where the two target metal ions share the identical stoichiometry with the hydrophilic complexing agents, the separation factors continuously increase with higher concentration of hydrophilic complexing agent.In contrast, when their stoichiometries differ, the separation factor reaches extreme values depending on the hydrophilic complexing agent concentrationAddnl., carefully designed "push-pull" extraction systems were exptl. tested, to verify the predicted extremum behavior of the separation factor.This study offers new insights into optimizing separation efficiency while minimizing the costs associated with hydrophilic complexing agents, providing practical implications for industrial extraction processes.

News (Medical) associated with Zinc Acetate

03 Mar 2025

·ir.etonpharma.com

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients – – $0 co-pay for all eligible patients and best-in-class patient support services – – Now available exclusively through Optime Care – DEER PARK, Ill., March 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has launched Galzin® (zinc acetate) capsules. Galzin is FDA-approved for the maintenance treatment of patients with Wilson disease who have been initially treated with a chelating agent. It is the only FDA-approved zinc therapy for Wilson disease. “We are excited to launch Galzin with our dedicated sales force and robust Eton Cares patient support services. Due to historic availability and affordability challenges, many patients have turned to unapproved compounded products or over-the-counter supplements to manage their Wilson disease. We are dedicated to increasing both access to and awareness of this critical medication. Through Eton Cares, we intend to ensure that every patient that needs Galzin will have access to it,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “As part of our commitment to the Wilson disease community, Eton is also actively investing in further research and development in an effort to drive meaningful advancements in treatment.” “Galzin is an important medication for Wilson disease patients, and we look forward to partnering with Eton to ensure patients have continued access to this drug,” said Rhonda Rowland, President, Wilson Disease Association. Galzin is now available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions. Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals. The program will provide prescription fulfillment, insurance benefits investigation, educational support, and qualified patient financial assistance, along with other services designed to help eligible patients access treatment. Eton Cares will offer $0 co-pay for all eligible patients. Clinicians seeking to prescribe Galzin can e-prescribe by selecting Optime Care as the pharmacy or fax in a patient referral form to 866-318-2990. Additional product details can be found on the product website, www.galzin.com. IMPORTANT SAFETY INFORMATION Warning and Precautions  Copper Deficiency: Several postmarketing cases reported that zinc acetate taken over extended periods of time (i.e., months to years) may result in decreased enteral copper absorption and copper deficiency. The cases reported the following complications of copper deficiency: anemia, granulocytopenia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, and myeloneuropathy. If a patient develops signs and/or symptoms of copper deficiency during treatment with zinc acetate, interrupt zinc treatment and measure zinc, 24-hr urinary copper, and non-ceruloplasmin bound copper (NCC) levels. Consider restarting zinc acetate treatment based on periodic monitoring of 24-hr urinary copper and NCC levels. Gastric Ulcer: There have been postmarketing reports of gastric ulcers with long-term use of zinc acetate. The cases reported the complications of anemia and gastric ulcer perforation with peritonitis. In some cases, ulcers persisted after treatment until zinc acetate was discontinued. If a patient develops signs and/or symptoms of gastric ulcer during treatment with zinc acetate, discontinue zinc treatment. Most patients showed improvement after cessation of zinc treatment. General: Zinc acetate is not recommended for the initial therapy of symptomatic patients because of the delay required for zinc-induced increase in enterocytic metallothionein and blockade of copper uptake. Symptomatic patients should be treated initially, using chelating agents. During initial therapy, neurological deterioration may occur as stores of copper are mobilized. Once initial therapy has been completed, and the patient is clinically stable, maintenance treatment with zinc acetate can be considered, but patients may be continued on initial therapy as clinically indicated. Information for Patients: Patients should take GALZIN® on an empty stomach, at least one hour before or two to three hours after meals. Capsules should be swallowed whole, not opened or chewed. In the rare event of gastric intolerance of zinc, generally occurring with the morning dose, this dose may be taken between breakfast and lunch. Patients must be clinically monitored to determine the adequacy of zinc acetate therapy. Since strict adherence to the zinc regimen is essential for optimal control of copper distribution and metabolism, the physician must reinforce the need for compliance at each contact with the patient.  Monitoring Patients: Patients should be monitored primarily by assessment of existing signs and symptoms of Wilson’s disease and 24-hour urine copper. Neuropsychiatric evaluations including speech as well as liver function tests including bilirubin and aminotransferases, should be done as appropriate. Adverse Reactions The following adverse reactions associated with the use of zinc acetate were identified from postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal disorders: gastric irritation Investigations: elevations of serum alkaline phosphatase, amylase, and lipase lasting from weeks to months suggesting pancreatitis; the levels usually return to high normal within the first one or two years of zinc therapy. INDICATION Zinc acetate therapy is indicated for maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent Please see Full Prescribing Information for more information. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX® (mecasermin) injection, ALKINDI SPRINKLE® (hydrocortisone) oral granules, GALZIN® (zinc acetate) capsules, PKU GOLIKE®, Carglumic Acid tablets, Betaine Anhydrous oral solution, and Nitisinone capsules. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia® (glyburide oral suspension), and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

Clinical ResultDrug Approval

07 Feb 2025

·ir.etonpharma.com

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

« Back to news - Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the product’s approval – DEER PARK, Ill., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent No. 12,214,010, covering its ET-600 product candidate’s proprietary formulation of desmopressin oral solution. The patent expires in 2044 and is expected to be listed in the FDA Orange Book upon the product’s approval. The Company has an additional patent application related to the product under review with the USPTO. ET-600 is a proprietary formulation of desmopressin oral solution under development for the treatment of diabetes insipidus. Desmopressin is the standard of care for diabetes insipidus, but there is not an FDA-approved oral liquid formulation. Currently, desmopressin is only FDA-approved in injectable, tablet, and nasal form, none of which fully meet the pediatric need for small, precise, and titratable doses. As a result, most pediatric patients use unapproved liquid suspensions from compounding pharmacies, attempt to cut and measure fractional tablets, or take daily injections. “This patent strengthens our growing intellectual property portfolio and underscores our commitment to delivering innovative treatments to underserved patient populations. The pediatric endocrinology community has expressed the significant need for a liquid form of desmopressin that can accurately and efficiently deliver small doses for children, and we are proud to have developed a formulation to meet their needs and to see our innovation recognized with a patent,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. ET-600 previously passed a pilot bioequivalence study in 2024 and is currently undergoing its pivotal bioequivalence study. The Company expects to have study results at the end of February. If results are positive, the company anticipates filing a New Drug Application (NDA) with the FDA for the product by the second quarter of 2025. About Diabetes Insipidus Diabetes insipidus is a rare condition in which the body produces too much urine and is not able to retain water. If left untreated, diabetes insipidus can cause excessive dehydration and delayed or stunted growth in children. The condition is estimated to affect about 1 in 25,000 people, or approximately 3,000 pediatric patients in the United States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

Drug ApprovalNDA

06 Feb 2025

·ir.etonpharma.com

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for ET-400. The new PDUFA goal date is May 28, 2025. The Company was notified that the FDA requires additional time to conduct a full review of supplemental information that was provided in December in response to an FDA request. The FDA communicated that it has applied a standard three-month extension from the original goal date of February 28, 2025. Eton believes it has fully addressed all questions from the FDA and there are no outstanding requests. “We are confident in the strength of our NDA package and look forward to ensuring access to patients in need of this important pediatric rare disease therapy immediately after FDA approval this year. We do not expect this standard extension to significantly affect our internal 2025 revenue projections,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

NDA

100 Deals associated with Zinc Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D06408	Zinc Acetate	A16AX05	DB14487

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Zinc deficiency	Japan	Nobelpharma Co., Ltd.	25 Jan 2008
Hepatolenticular Degeneration	United States	Eton Pharmaceuticals, Inc.	28 Jan 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Deficiency Diseases	Phase 3	Japan	Nobelpharma Co., Ltd.	01 Jan 2015
Erythema Infectiosum	Phase 3	-	Nobelpharma Co., Ltd.	01 Oct 2004
Amyotrophic Lateral Sclerosis	Phase 1	United States	Theriva Biologics, Inc.	30 Nov 2011
Diabetic Nephropathies	Preclinical	Japan	Asahikawa Medical University	16 Sep 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05130814 (RISE_UP, CTgov)	Not Applicable	Pressure Ulcer	48	bandage+zinc+hyaluronic acid gauze plus polyurethane foam+hyaluronic acid sodium salt+metallic silver (Control Group)	fxmrceylzy(ovzqoafxac) = sycugtujku jgryrmpanm (xgucgnvvzv, ydmxjavags - mgmcvoqxru) View more	-	28 Jan 2025
				bandage+zinc+hyaluronic acid gauze plus polyurethane foam+hyaluronic acid sodium salt+metallic silver (EmoLED Group)	fxmrceylzy(ovzqoafxac) = negutrwdqq jgryrmpanm (xgucgnvvzv, mzyptrwtrv - wncofvkowc) View more
ATS2024	Not Applicable	-	-	Zinc (ZinPro)	utaqqnhdfr(ezuhkehnfc) = blxjkocvmk hywqmkqosy (xbyerhyinv )	-	19 May 2024
DDW2024	Not Applicable	Hepatic Encephalopathy	-	No zinc supplementation	ddhmjxdrqk(tjxjnbkwtm) = hofrebgixp gtfwopzdjk (tijytbvhtl ) View more	-	18 May 2024
ASH2023	Not Applicable	Anemia \| Zinc deficiency \| Chronic Kidney Diseases	34	Zinc Sulfate 50 mg	ardowiohtr(kzewyzhwan) = upzxqimafs wdlwpiiyaz (crvklxkupb )	-	11 Dec 2023
EADV2023	Not Applicable	Acne Vulgaris	67	Facial night serum with retinaldehyde, zinc PCA, and niacinamide	ylqulcuxxo(phkyazctag) = 4 out of 67 subjects reported mild events ( burning and itching ) in specific applications that receded almost immediately kxfyragimf (djkarargxs ) View more	Positive	11 Oct 2023
EANM2021	Not Applicable	99mTc-sestamibi	29	cadmium-zinc-telluride camera (Left Atrium (LA))	mfmmsqscjc(cnkzsyxyoe) = kqhoeusorp gxaxmptkcn (eiblcqitsw ) View more	-	24 Sep 2021
				cadmium-zinc-telluride camera (Left Ventricle (LV))	mfmmsqscjc(cnkzsyxyoe) = bmzvvonpwm gxaxmptkcn (eiblcqitsw ) View more
Pubmed \| Biol Trace Elem Res	Not Applicable	-	-	Preventive zinc dispersible tablet (7 mg/d)	sovktquigv(nvprxshtkn) = piobaroxah vdawrzymkp (okbfbkjxjr )	-	01 Feb 2021
				Micronutrient powder (10 mg zinc/d)	sovktquigv(nvprxshtkn) = cxeajyeqcb vdawrzymkp (okbfbkjxjr )
NCT03135522 (ZICO, CTgov)	Phase 2	Refractory chronic cough	34	Zinc Acetate 50 Mg Oral Capsule (Zinc Acetate 50 mg Oral Capsule)	luccheguwr(xzissxsywl) = vpivdhxoge kuovtbbqmz (hitcutseiz, kjouxemekp - wurlqrvzjx) View more	-	22 Dec 2020
				Placebo oral capsule (Placebo Oral Capsule)	luccheguwr(xzissxsywl) = unhzwgkfyr kuovtbbqmz (hitcutseiz, meoljxnydq - fzcspjlkrx) View more
ASN2020	Not Applicable	Chronic Kidney Diseases	325	Zinc (Zn levels<60 μ g/dl)	lkafaoqbjz(smhedkeggl) = jnxahdkhqy gdpctymqbx (kzxrtalojy )	Positive	19 Oct 2020
				Zinc (Zn levels ≥ 60 μ g/dl)	lkafaoqbjz(smhedkeggl) = onjxebrhvl gdpctymqbx (kzxrtalojy )
NCT02337569 (Pubmed \| Biol Trace Elem Res) Manual	Phase 3	Liver Diseases	57	NPC-02	wjodvgbtbt(uiutbwirzv) = otilxephrk bnizqocbyw (nqiaslmwlm, 20.2) View more	Positive	01 May 2020
				Placebo	wjodvgbtbt(uiutbwirzv) = dkqctsxvjd bnizqocbyw (nqiaslmwlm, 12.0) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Zinc Acetate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation